Skip to main content
Erschienen in: Herz 6/2019

16.07.2019 | Main topic

Pulmonary hypertension and valvular heart disease

verfasst von: T. Tichelbäcker, D. Dumitrescu, F. Gerhardt, D. Stern, M. Wissmüller, M. Adam, T. Schmidt, C. Frerker, R. Pfister, M. Halbach, S. Baldus, Prof. Dr. S. Rosenkranz

Erschienen in: Herz | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary hypertension (PH) is an important contributor to morbidity and mortality in patients with left-sided heart disease, including valvular heart disease. In this context, elevated left atrial pressure primarily leads to the development of post-capillary PH. Despite the fact that repair of left-sided valvular heart disease by surgical or interventional approaches will improve PH, recent studies have highlighted that PH (pre- or post-interventional) remains an important predictor of long-term outcome. Here, we review the current knowledge on PH in valvular heart disease taking into account new hemodynamic PH definitions, and the distinction between post- and pre-capillary components of PH. A specific focus is on the precise characterization of hemodynamics and cardiopulmonary interaction, and on potential strategies for the management of residual PH after mitral or aortic valve interventions. In addition, we highlight the clinical significance of tricuspid regurgitation, which may occur as a primary condition or as a consequence of PH and right heart dilatation (functional). In this context, proper patient selection for potential tricuspid valve interventions is crucial. Finally, the article highlights gaps in evidence, and points toward future perspectives.
Literatur
1.
Zurück zum Zitat Hoeper MM, Humbert M, Souza R et al (2016) A global view of pulmonary hypertension. Lancet Respir Med 4:306–322CrossRefPubMed Hoeper MM, Humbert M, Souza R et al (2016) A global view of pulmonary hypertension. Lancet Respir Med 4:306–322CrossRefPubMed
2.
Zurück zum Zitat Simonneau G, Montani D, Celermajer DS et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53:1801913CrossRefPubMedPubMedCentral Simonneau G, Montani D, Celermajer DS et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53:1801913CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954CrossRefPubMed Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954CrossRefPubMed
4.
Zurück zum Zitat Zlotnick DM, Ouellette ML, Malenka DJ et al (2013) Effect of pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol 112:1635–1640CrossRefPubMed Zlotnick DM, Ouellette ML, Malenka DJ et al (2013) Effect of pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol 112:1635–1640CrossRefPubMed
5.
Zurück zum Zitat Melby SJ, Moon MR, Lindman BR et al (2011) Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg 141:1424–1430CrossRefPubMedPubMedCentral Melby SJ, Moon MR, Lindman BR et al (2011) Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg 141:1424–1430CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Yang B, De Benedictus C, Watt T et al (2016) The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis. J Thorac Cardiovasc Surg 152:394–400CrossRefPubMed Yang B, De Benedictus C, Watt T et al (2016) The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis. J Thorac Cardiovasc Surg 152:394–400CrossRefPubMed
7.
Zurück zum Zitat O’Sullivan CJ, Wenaweser P, Ceylan O et al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358PubMed O’Sullivan CJ, Wenaweser P, Ceylan O et al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358PubMed
8.
Zurück zum Zitat Luçon A, Oger E, Bedossa M et al (2014) Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 registry. Circ Cardiovasc Interv 7:240–247CrossRefPubMed Luçon A, Oger E, Bedossa M et al (2014) Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 registry. Circ Cardiovasc Interv 7:240–247CrossRefPubMed
9.
Zurück zum Zitat Sinning JM, Hammerstingl C, Chin D et al (2014) Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention 9:1042–1049CrossRefPubMed Sinning JM, Hammerstingl C, Chin D et al (2014) Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention 9:1042–1049CrossRefPubMed
10.
Zurück zum Zitat Masri A, Abdelkarim I, Sharbaugh MS et al (2018) Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement. Heart 104:821–827CrossRefPubMed Masri A, Abdelkarim I, Sharbaugh MS et al (2018) Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement. Heart 104:821–827CrossRefPubMed
11.
Zurück zum Zitat Tigges E, Blankenberg S, von Bardeleben RS et al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585–594CrossRefPubMed Tigges E, Blankenberg S, von Bardeleben RS et al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585–594CrossRefPubMed
12.
Zurück zum Zitat Mentias A, Patel H, Patel K et al (2016) Effect of pulmonary vascular pressures on long-term outcome in patients with primary mitral regurgitation. J Am Coll Cardiol 67:2952–2961CrossRefPubMed Mentias A, Patel H, Patel K et al (2016) Effect of pulmonary vascular pressures on long-term outcome in patients with primary mitral regurgitation. J Am Coll Cardiol 67:2952–2961CrossRefPubMed
13.
Zurück zum Zitat Gual-Capllonch F, Teis A, Ferrer E et al (2018) Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography 35:1736–1745CrossRefPubMed Gual-Capllonch F, Teis A, Ferrer E et al (2018) Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography 35:1736–1745CrossRefPubMed
14.
Zurück zum Zitat Taramasso M, Pazzoli A, Basso C et al (2018) Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies. EuroIntervention 13:1889–1898CrossRef Taramasso M, Pazzoli A, Basso C et al (2018) Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies. EuroIntervention 13:1889–1898CrossRef
15.
Zurück zum Zitat Galiè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119CrossRefPubMed Galiè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119CrossRefPubMed
16.
Zurück zum Zitat Maron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 133:1240–1248CrossRefPubMedPubMedCentral Maron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 133:1240–1248CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Assad TR, Maron BA, Robbins IM et al (2017) Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol 2:1361–1368CrossRefPubMedPubMedCentral Assad TR, Maron BA, Robbins IM et al (2017) Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol 2:1361–1368CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Douschan P, Kovacs G, Avian A et al (2018) Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 197:509–516CrossRefPubMed Douschan P, Kovacs G, Avian A et al (2018) Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 197:509–516CrossRefPubMed
19.
Zurück zum Zitat Kolte D, Lakshmanan S, Jankowich MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7:e9729CrossRefPubMedPubMedCentral Kolte D, Lakshmanan S, Jankowich MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 7:e9729CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Vachiéry JL, Tedford RJ, Rosenkranz S et al (2019) Pulmonary hypertension due to left heart disease. Eur Respir J. https://doi.org/10.1183/13993003.01897–2018 Vachiéry JL, Tedford RJ, Rosenkranz S et al (2019) Pulmonary hypertension due to left heart disease. Eur Respir J. https://​doi.​org/​10.​1183/​13993003.​01897–2018
21.
Zurück zum Zitat Rosenkranz S, Lang IM, Blind R et al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 272:S53–S62CrossRef Rosenkranz S, Lang IM, Blind R et al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 272:S53–S62CrossRef
22.
Zurück zum Zitat Vanderpool RR, Saul M, Nouraie M et al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in patients with heart failure and preserved ejection fraction. JAMA Cardiol 3:298–306CrossRefPubMedPubMedCentral Vanderpool RR, Saul M, Nouraie M et al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in patients with heart failure and preserved ejection fraction. JAMA Cardiol 3:298–306CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left-heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and new insights for future changes. Eur J Heart Fail 20:248–255CrossRefPubMed Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left-heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and new insights for future changes. Eur J Heart Fail 20:248–255CrossRefPubMed
24.
Zurück zum Zitat Caravita S, Dewachter C, Soranna D et al (2018) Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur Respir J 51(4):1702427CrossRefPubMed Caravita S, Dewachter C, Soranna D et al (2018) Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur Respir J 51(4):1702427CrossRefPubMed
25.
Zurück zum Zitat Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69:1718–1734CrossRefPubMed Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69:1718–1734CrossRefPubMed
26.
27.
Zurück zum Zitat Wood P, Besterman EM, Towers MK, Mcilroy MB (1957) The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J 19:279–286CrossRefPubMedPubMedCentral Wood P, Besterman EM, Towers MK, Mcilroy MB (1957) The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J 19:279–286CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Braunwald E, Braunwald NS, Ross J, Morrow AG (1965) Effects of mitral valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 273:509–514CrossRefPubMed Braunwald E, Braunwald NS, Ross J, Morrow AG (1965) Effects of mitral valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N Engl J Med 273:509–514CrossRefPubMed
29.
Zurück zum Zitat Dalen JE, Matloff JM, Evans GL et al (1967) Early reduction of pulmonary vascular resistance after mitral-valve replacement. N Engl J Med 277:387–394CrossRefPubMed Dalen JE, Matloff JM, Evans GL et al (1967) Early reduction of pulmonary vascular resistance after mitral-valve replacement. N Engl J Med 277:387–394CrossRefPubMed
30.
Zurück zum Zitat Dev V, Shrivastava S (1991) Time course of changes in pulmonary vascular resistance and the mechanism of regression of pulmonary arterial hypertension after balloon mitral valvuloplasty. Am J Cardiol 67:439–442CrossRefPubMed Dev V, Shrivastava S (1991) Time course of changes in pulmonary vascular resistance and the mechanism of regression of pulmonary arterial hypertension after balloon mitral valvuloplasty. Am J Cardiol 67:439–442CrossRefPubMed
31.
Zurück zum Zitat Tsukashita M, Takayama H, Takeda K et al (2015) Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival. J Thorac Cardiovasc Surg 150:1352–1361CrossRefPubMed Tsukashita M, Takayama H, Takeda K et al (2015) Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival. J Thorac Cardiovasc Surg 150:1352–1361CrossRefPubMed
32.
Zurück zum Zitat Al Kindi SG, Farhoud M et al (2017) Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J Card Fail 23:209–215CrossRef Al Kindi SG, Farhoud M et al (2017) Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J Card Fail 23:209–215CrossRef
33.
Zurück zum Zitat Imamura F, Chung B, Nguyen A et al (2017) Decoupling between diastolic pulmonary artery pressure and pulmonary capillary wedge pressure as a prognostic factor after continuous flow ventricular assist device implantation. Circ Heart Fail 10:e3882CrossRefPubMedPubMedCentral Imamura F, Chung B, Nguyen A et al (2017) Decoupling between diastolic pulmonary artery pressure and pulmonary capillary wedge pressure as a prognostic factor after continuous flow ventricular assist device implantation. Circ Heart Fail 10:e3882CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bursi F, Barbieri A, Grigioni F et al (2010) Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 12:382–388CrossRefPubMed Bursi F, Barbieri A, Grigioni F et al (2010) Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 12:382–388CrossRefPubMed
35.
Zurück zum Zitat Lancellotti P, Magne J, Dulgheru R et al (2015) Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol 115:1454–1461CrossRefPubMed Lancellotti P, Magne J, Dulgheru R et al (2015) Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol 115:1454–1461CrossRefPubMed
36.
Zurück zum Zitat Kusunose K, Popović ZB, Motoki H, Marwick TH (2013) Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging 6:167–176CrossRefPubMed Kusunose K, Popović ZB, Motoki H, Marwick TH (2013) Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging 6:167–176CrossRefPubMed
37.
Zurück zum Zitat Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126–132CrossRefPubMed Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126–132CrossRefPubMed
38.
Zurück zum Zitat Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307–2318CrossRef Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379:2307–2318CrossRef
39.
Zurück zum Zitat Faggiano P, Antonini-Canterin F, Ribichini F et al (2000) Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 85:204–208CrossRefPubMed Faggiano P, Antonini-Canterin F, Ribichini F et al (2000) Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 85:204–208CrossRefPubMed
40.
Zurück zum Zitat Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81–88CrossRefPubMed Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81–88CrossRefPubMed
41.
Zurück zum Zitat Roques F, Nashef SA, Michel P et al (1999) Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15:816–822CrossRefPubMed Roques F, Nashef SA, Michel P et al (1999) Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15:816–822CrossRefPubMed
42.
Zurück zum Zitat Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198CrossRef Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198CrossRef
43.
Zurück zum Zitat Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331CrossRefPubMed Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331CrossRefPubMed
44.
Zurück zum Zitat Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620CrossRefPubMed Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620CrossRefPubMed
45.
Zurück zum Zitat Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1706–1715CrossRef Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1706–1715CrossRef
46.
Zurück zum Zitat Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621CrossRefPubMedPubMedCentral Fisher MR, Forfia PR, Chamera E et al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615–621CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Marciniak A, Klover K, Sharma R (2017) Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open 7:e12240CrossRefPubMedPubMedCentral Marciniak A, Klover K, Sharma R (2017) Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open 7:e12240CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Wang N, Fulcher J, Abeysuriya N et al (2019) Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J 40:476–484CrossRefPubMed Wang N, Fulcher J, Abeysuriya N et al (2019) Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J 40:476–484CrossRefPubMed
49.
Zurück zum Zitat Topilsky Y, Maltais S, Medina Inojosa J et al (2019) Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 12:433–442CrossRefPubMed Topilsky Y, Maltais S, Medina Inojosa J et al (2019) Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 12:433–442CrossRefPubMed
50.
Zurück zum Zitat Topilsky Y, Nkomo VT, Vatury O et al (2014) Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 7:1185–1194CrossRefPubMed Topilsky Y, Nkomo VT, Vatury O et al (2014) Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 7:1185–1194CrossRefPubMed
51.
Zurück zum Zitat Nickenig G, Kowalsi M, Hausleiter J et al (2017) Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 135:1802–1814CrossRefPubMed Nickenig G, Kowalsi M, Hausleiter J et al (2017) Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 135:1802–1814CrossRefPubMed
52.
Zurück zum Zitat Prihadi EA, van der Bijl P, Gursoy E et al (2018) Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart J 39:3574–3581CrossRefPubMed Prihadi EA, van der Bijl P, Gursoy E et al (2018) Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart J 39:3574–3581CrossRefPubMed
53.
Zurück zum Zitat Prihadi EA, Delgado V, Leon MB et al (2019) Morphologic types of tricuspid regurgitation: characteristics and prognostic implications. JACC Cardiovasc Imaging 12:491–499CrossRefPubMed Prihadi EA, Delgado V, Leon MB et al (2019) Morphologic types of tricuspid regurgitation: characteristics and prognostic implications. JACC Cardiovasc Imaging 12:491–499CrossRefPubMed
54.
Zurück zum Zitat Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41:462–468CrossRefPubMed Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41:462–468CrossRefPubMed
55.
Zurück zum Zitat Mahmud E, Madani MM, Kim NH et al (2018) Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol 71:2468–2486CrossRefPubMed Mahmud E, Madani MM, Kim NH et al (2018) Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol 71:2468–2486CrossRefPubMed
56.
Zurück zum Zitat Medvedofsky D, Aronson D, Gomberg-Maitland M et al (2017) Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging 18:86–94CrossRefPubMed Medvedofsky D, Aronson D, Gomberg-Maitland M et al (2017) Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging 18:86–94CrossRefPubMed
57.
Zurück zum Zitat De Meester P, De Cock D, Van De Bruaene A et al (2015) Additional tricuspid annuloplasty in mitral valve surgery results in better clinical outcome. Heart 101:720–726CrossRefPubMed De Meester P, De Cock D, Van De Bruaene A et al (2015) Additional tricuspid annuloplasty in mitral valve surgery results in better clinical outcome. Heart 101:720–726CrossRefPubMed
58.
Zurück zum Zitat Chickwe J, Itagaki S, Anyanwu A, Adams DH (2015) Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 65:1931–1938CrossRef Chickwe J, Itagaki S, Anyanwu A, Adams DH (2015) Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 65:1931–1938CrossRef
59.
Zurück zum Zitat Borlaug B, Kane GC, Melenovsky V, Olson TP (2016) Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 37:3293–3302PubMed Borlaug B, Kane GC, Melenovsky V, Olson TP (2016) Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 37:3293–3302PubMed
60.
Zurück zum Zitat Kang DH, Park SJ, Shin SH et al (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139:1354–1365CrossRefPubMed Kang DH, Park SJ, Shin SH et al (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139:1354–1365CrossRefPubMed
61.
Zurück zum Zitat Bermejo J, Yotti R, García-Orta R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39:1255–1264CrossRefPubMed Bermejo J, Yotti R, García-Orta R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39:1255–1264CrossRefPubMed
62.
Zurück zum Zitat Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791CrossRefPubMed Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791CrossRefPubMed
Metadaten
Titel
Pulmonary hypertension and valvular heart disease
verfasst von
T. Tichelbäcker
D. Dumitrescu
F. Gerhardt
D. Stern
M. Wissmüller
M. Adam
T. Schmidt
C. Frerker
R. Pfister
M. Halbach
S. Baldus
Prof. Dr. S. Rosenkranz
Publikationsdatum
16.07.2019
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 6/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-019-4823-6

Weitere Artikel der Ausgabe 6/2019

Herz 6/2019 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.